医学状况复杂患者的牙周管理专家共识发布
Expert consensus on periodontal management for medically compromised patients
国际口腔科学杂志发表专家共识,系统梳理牙周炎与糖尿病、心血管疾病、骨质疏松、呼吸系统疾病、肝肾疾病、肿瘤及血液病等的双向关联机制,并提出分层治疗策略。共识建议按HbA1c水平、血压分级及凝血指标进行风险分层,明确妊娠期、化疗期及抗吸收药物使用期间的牙周干预时机,为全身合并症患者提供操作指引。
多专科专家联合制定,按HbA1c及血压等分层给出牙周治疗时机与方案调整建议,便于临床医生快速对照决策。
译文尚不完整,完整内容请切换到原文。
- Review Article
- 开放获取
- 发表日期: 2026年11月20日
- 耿福雪1 na1,
- 林莉1 na1,
- 宋忠辰2,
- 阎福华3,
- 徐yan4,
- 刘yi ORCID: orcid.org/0000-0002-4998-55475,
- 孙江6,
- 栾庆贤7,
- 胡文杰8,
- 葛少华 ORCID: orcid.org/0000-0003-3821-54809,
- 陈发明 ORCID: orcid.org/0000-0002-8398-210410,
- 赵传江11,
- 乔杰12,
- 陈小平13,
- 左向豪14,
- 刘兴辉15,
- 安利16,
- 王祖民17,
- 张东梅1,
- 李chen1,
- 赵喜达1,
- 丁yi18 &
- …
- 潘亚平 ORCID: orcid.org/0000-0001-6711-899219
国际口腔科学杂志 第18卷 , 文章编号: 74 (2026) 引用本文
摘要
牙周炎是一种高度普遍的口腔疾病,其影响不仅限于局部炎症和组织破坏,还会对全身健康产生深远的影响。随着多病共存负担的增加,多种全身性疾病经常同时存在,牙周管理变得越来越复杂,但针对这一特定患者群体的明确和综合指导仍然有限。本文综合了当前关于牙周炎与全身状况双向关系的证据,提出了动态牙周管理的建议,并更新了相关的治疗策略。该专家共识旨在确保牙周治疗的安全性和有效性,降低并发症风险,最终促进口腔和整体健康。
引言
牙周炎是全球性的健康挑战,发病率高。未经控制的牙周炎会导致牙周组织的破坏,最终导致牙齿脱落。全球疾病负担(GBD)数据显示,口腔疾病的影响预计会有显著增加。全球范围内,重度牙周炎预计将在2050年上升至第30位(从2021年的第31位),而无牙状态则预计会有更显著的上升,从第24位跃升至第15位。1中国是牙周病负担较重的国家之一,预计到2050年将有约1.3023亿无牙患者,这占全球负担的19.67%。2同时,中国面临着严重的全身性疾病负担。3,4
牙周炎的影响远不止局部炎症,而是成为一种持续的全身炎症负担的来源。如最近所回顾的,5牙周炎症的全身影响是通过一系列相互关联的途径介导的,包括微生物转移及其毒力因子和代谢产物,激活的口腔免疫细胞和局部产生的自身抗体的动员,口腔-肠道微生物失调,训练性免疫维持慢性高炎症状态,细胞衰老,多种表观遗传改变,以及严重情况下咀嚼功能障碍引起的营养/代谢紊乱。这些机制的结合强化了牙周健康对全身健康的整合观念。6,7,8,9,10值得注意的是,牙周炎被发现显著增加了全因和特定原因的死亡风险。11因此,全面评估全身因素的个性化牙周管理对于降低治疗风险、提高治疗效果并最终促进口腔和全身健康至关重要。12随着系统因素与牙周炎相互作用的持续研究以及这些系统性疾病药物治疗的发展,全面的牙周管理原则的需求越来越明显。
接下来的章节中,首先描述了该共识的发展过程和具体方法,然后概述了牙周管理的一般原则(图. 1)。对于每种情况,我们提供:(i)其最新的流行病学背景和潜在的分子机制的简要介绍;(ii)动态牙周管理的临床指导建议,包括当需要时的种植体治疗;(iii)临床注意事项;以及(iv)双向治疗益处的最新进展。
动态牙周管理的整体临床流程图。CVDs 心血管疾病,CKD 肾脏疾病,OHI 口腔卫生指导
方法
该共识由中国牙科协会牙周病分会的专家与心血管医学、内分泌学、呼吸医学和妇产科多学科专家合作发起。
该共识涉及的全身性疾病,包括糖尿病、心血管疾病、骨质疏松、呼吸系统疾病、肝/肾疾病、癌症、血液系统疾病和激素失衡等,均根据其与牙周炎的相关性或对牙周治疗的影响,特别是治疗安全性和风险管理方面进行选择。传染病不是该共识的主要关注点,但在相关章节中简要讨论了特定的传染病对交叉感染控制的影响,其他传染病不在讨论范围内。对牙周炎及相关全身性疾病的高质量临床研究、荟萃分析、系统评价、临床指南、专家共识和权威教科书进行了系统文献检索。
临床指导建议的分级:我们采用了欧洲心脏病学会(ESC)2024年治疗和预防的证据等级系统,并进行了轻微修改:A级表示来自≥2项充分动力的随机对照试验(RCTs)的结论性证据;B级表示来自≥1项RCT或≥2项动力学非随机研究的提示性/有限证据,或来自临床指南、专家共识或权威教科书的证据,将B1和B2子级别合并为单一的B级,以提高临床应用性;C级表示基于专家经验或临床逻辑的初步证据。13
根据研究设计和质量,由两位核心专家独立评分,分歧通过讨论解决。对于源自先前发表的共识声明的建议,追溯并验证了原始证据。通过两轮修改德尔菲过程达成共识,共识定义为≥80%的专家组成员在9点李克特量表上给出7分或更高分。14本论文中的所有建议在审查过程中均达成共识(总体一致率>95%)。评分显示在每个建议之后,格式为[A]/[B]/[C]。所有建议的总结及其评分理由见表 S1。
一般原则和综合管理框架
提高牙周健康意识
-
应加强关于口腔卫生的重要性、定期口腔检查的价值以及牙周健康对整体健康的作用的科普宣传。
-
建议医生提醒患有全身性疾病的患者注意牙周炎与某些全身性疾病之间的双向易感性,定期进行口腔检查,并接受必要的牙周治疗。
-
对于某些全身性疾病,症状有时可能在牙科诊所首次被发现。因此,牙医应建议出现某些口腔症状的患者进行必要的全身检查和治疗。
术前评估
-
为了识别全身性疾病或检测潜在的疾病,详细的全身性疾病、用药和家族史询问,结合牙周和相关实验室检查是必不可少的。
风险分层和治疗调整 本共识采用EFP S3级四步框架(第1步:风险因素控制和专业机械性牙菌斑清除(PMPR);第2步:根面刮治;第3步:牙周手术;第4步:支持性牙周治疗(SPC))来指导各疾病特定章节中列出的治疗调整。在适当的情况下,我们已在相应的建议旁边标明了相关步骤。
-
对于出现急性症状的患者,在进行牙周干预前应寻求相关医师的建议。
-
应根据患者的临床状况制定个性化的长期治疗策略。
-
对于牙周炎晚期患者,需要多学科联合治疗以恢复完整的牙齿和咀嚼功能,这将有助于改善牙周和全身健康。15
支持性治疗
-
在支持性治疗期间,每次就诊时都应强调口腔卫生指导和复发的可能性。
-
在积极牙周治疗后的前12个月内,患者应定期在第3个月、第6个月和第12个月进行随访。在最初的12个月之后,随访间隔不建议超过6至12个月。随访间隔可根据个人情况调整,如口腔卫生状况、牙周检查结果和全身状况。16
-
支持性治疗应根据随访期间牙周检查的结果进行。
糖尿病
背景
糖尿病(DM)是高发病率和高死亡率的非传染性疾病之一。根据GBD研究,从2005年到2024年,2024年将有5.89亿成人患有糖尿病。展望未来,预计到2050年,成人糖尿病患者人数将达到约8.53亿。17
由于空腹血糖水平高、高体重指数(BMI)、饮食相关因素和空气污染等风险因素,中国目前承担了最大的糖尿病负担,占全球病例的25.1%。在中国,超过90%的糖尿病病例是2型糖尿病(T2DM)。同时,中国诊断为糖尿病前期的人口比例相当高。更严重的是,估计有60%的糖尿病患者对自己的状况一无所知,导致大量未诊断的糖尿病患者。18,19,20
糖尿病是2018年牙周炎新分类中的一个分级因素。21 根据最近的荟萃分析,患有牙周炎的个体患2型糖尿病的风险比正常人高19%到26%,而糖尿病患者则经历显著更高的牙齿丧失率。22 牙周炎的全身效应主要由微生物转移和全身炎症负荷驱动。在高血糖条件下,这些反应会被放大。新兴证据表明,表观遗传重编程触发了适应不良的髓系祖细胞分化和训练的固有免疫,随后使单核巨噬细胞极化为促炎表型,并扰乱宿主-微生物平衡。23,24 同时,免疫代谢改变,如异常的糖酵解,会损害成骨分化并加剧牙槽骨丧失。25
临床指导建议
术前评估
风险分层与治疗调整
根据患者的HbA1c水平,对牙周管理进行分层调整(图. 2)
-
对于血糖控制理想(HbA1c < 6.5%)的患者:治疗计划应与非糖尿病患者相同。28 [B]
-
对于血糖控制良好(HbA1c 6.5–7.5%)的患者:可以制定常规治疗计划,而步骤1和2非手术牙周治疗(NSPT)应优先考虑。28 [B]
-
当血糖水平控制不佳(HbA1c > 7.5%)时:推荐基于象限的步骤1和2非手术牙周治疗(NSPT)而非全口治疗方案,以缩短每次治疗时间并防止急性期反应。29 [B] 对于可能需要步骤3手术治疗的患者,HbA1c 应低于8%。30 [B]
-
对于血糖控制差(HbA1c > 10%)的患者:应仅进行紧急治疗以控制急性牙周感染,直到血糖水平得到有效控制。30 [B]
临床注意事项
根据现有证据,牙周治疗在糖尿病患者中通常是安全和有效的。31 然而,随着糖尿病严重程度的增加,挑战也随之增加。除了上述的程序调整外,在牙周管理期间,临床医生还应关注以下全身性和跨学科的注意事项:
-
双向链接—筛查和跨学科转诊:对于牙周炎患者,尤其是那些具有高空腹血糖、高BMI和饮食相关因素等风险因素的患者,应考虑常规筛查糖尿病和糖尿病前期。同时,内分泌科医生应将已确诊糖尿病且血糖控制不佳的患者转介进行牙周检查和治疗。31
-
术中低血糖预防:接受胰岛素、磺脲类药物或其他降糖药物的患者应在手术前咨询其医生,以便调整用药方案,预防术中低血糖。15
-
术后并发症:临床医生应意识到,未控制的糖尿病会增加术后牙周手术并发症,如肿胀、出血、感染、伤口愈合延迟和瓣膜裂开。32
治疗益处
近年来,牙周炎与糖尿病之间的双向关系受到了越来越多的关注。31 在患有牙周炎和2型糖尿病的患者中,将PMPR与透明质酸凝胶、益生菌或抗生素联合使用,比单独使用PMPR能获得更大的临床改善和更大的HbA1c降低。33,34,35 尤其是在改善中重度牙周炎2型糖尿病患者的血糖调节方面,逐步牙周治疗策略,包括非手术牙周治疗、必要的牙周手术和牙周维护,已经显示出比常规牙龈上洁治和抛光更显著的优势。36 相反,糖尿病的存在被发现会显著降低牙周治疗的效果。37
由于高血糖的炎症微环境,导致炎症级联反应加剧、氧化应激反应和胶原合成失调,25,38,39 目前尚未找到一种临床有效的治疗方法能够实现理想的牙周骨再生。40 多种策略,如新型材料(例如超分子光热材料和载药微球)和治疗方法(例如激光治疗),正在测试中以促进糖尿病患者的组织再生。40,41,42
心血管疾病
背景
心血管疾病(CVDs)是指包括冠心病、动脉粥样硬化、风湿性心脏病、高血压和心力衰竭等一系列病理状态。作为导致死亡的主要原因,GBD 2023估计全球现患CVD病例数为6.26亿。43 在中国,随着老龄化人口和未控制的代谢风险因素的双重挑战,CVDs的发病率正在增加;已有超过3.3亿人被诊断为CVDs。44 通常,最新的荟萃分析表明,牙周炎与CVDs的风险增加31%相关。45 以高血压患者为例,这些患有牙周炎的人的CVD死亡风险显著高于无牙周炎的人。46 同样,患有颈动脉粥样硬化(CAS)的患者比无CAS的患者有更高的重度牙周炎患病率。47
牙周炎与心血管疾病(CVDs)之间的机制相互作用是多方面的。牙周病原体可以直接侵入血管内皮,损害内皮完整性和功能。48,49 同时,骨髓-血管轴通过调节训练过的髓系细胞来影响局部血管炎症,从而增加心血管疾病的风险。50,51 最近的研究重点转向了口腔-肠道微生物群,其中菌群失调被认为通过细菌代谢产物和毒力因子触发心血管功能障碍。52
临床指导建议
术前评估
风险分层与治疗调整
通常,牙周治疗被认为在心血管疾病风险方面是安全的。55 对于心血管疾病患者,NSPT的第1步和第2步,考虑在多个较短的会诊期内进行牙周治疗,因为高强度方案(24小时内全口治疗)已被证明会引发炎症标志物的暂时性升高和内皮功能障碍。56
高血压
-
基础条件(130 – 139/80 – 89 mmHg):治疗计划应与正常血压人群相同。 [B]
-
第一级(140 – 159/90 – 99 mmHg):每次就诊时均需测量血压。治疗计划应与无高血压患者相同。 [B]
-
第二级(160 – 179/100 – 109 mmHg):在这种情况下,更推荐进行NSPT的第1步和第2步。在患者血压得到充分控制后,才可进行第3步牙周手术。55 [B]
-
第三级(超过180/110 mmHg):应首先启动积极的心血管治疗,仅在急性牙周感染时提供紧急治疗。 [B]
异常凝血功能
当心血管疾病患者出现凝血功能异常或正在接受抗血小板和抗凝治疗(如阿司匹林、氯吡格雷、利伐沙班和华法林)时,应相应调整牙周和全身治疗计划(图 3)。
-
牙周治疗调整:当血小板计数低于80 × 109/L时,不推荐进行第3步牙周手术。当血小板计数低于60 × 109/L时,甚至第1步和第2步NSPT也不推荐。进行牙槽外科手术的患者INR应维持在3.5以下。30,57 [B]
-
抗血小板/抗凝治疗管理:目前没有证据支持在低出血风险的治疗中因不同剂量的抗血小板疗法而中断治疗。对于INR为3.5或更高的患者,在进行低到中等出血风险的牙周治疗前,建议在与负责的医疗专业人员协商后停用抗凝药物(例如华法林)。55 [B]
-
关键阈值:血小板计数低于50×10⁹/L或INR为3.5或更高被视为关键阈值,在进行牙周治疗前应咨询合格的医疗专业人员。58 [B]
异常凝血参数患者的决策图。26,30,57,58,209 *低出血风险组包括非手术牙周治疗(NSPT)、常规牙周手术(保守、切除或再生性手术)、拔牙和种植体植入。中等出血风险组包括大多数自体骨增量手术、上颌窦提升术和软组织手术(例如游离龈瓣移植和结缔组织移植)。CVDs:心血管疾病;INR:国际标准化比值;NSPT:非手术牙周治疗
其他急性状况
临床注意事项
-
抗生素预防—跨学科协调:考虑到通过牙周检查和治疗可能引起的血流中细菌定植,对于先天性心脏病、心脏瓣膜置换、感染性心内膜炎(IE)病史或心脏移植后的瓣膜性心脏病患者,建议预防性使用抗生素。30,60 对于高风险IE的成人患者,根据2023年ESC指南建议进行预防性抗生素治疗。应在手术前30至60分钟内给予单次剂量的抗生素预防。对于无青霉素过敏的患者,首选阿莫西林;替代药物包括氨苄西林、头孢唑林或头孢曲松。对于青霉素过敏的患者,口服选项包括头孢氨苄、阿奇霉素、克拉霉素或多西环素。对于儿科患者,剂量应根据体重、年龄和过敏史进行调整。61
-
术中止血—局部措施和医疗咨询:在CVD患者中,尤其是正在接受抗凝和/或抗血小板治疗或高血压控制不佳的患者,牙周袋深处的持续出血较为常见。62 应注意,大多数术中出血可以通过局部止血措施(如局部压迫、可吸收明胶海绵和缝合)得到有效控制。55 当牙龈出血无法通过局部止血治疗有效控制时,建议及时咨询医生以采取其他措施。此外,在与CVD相关的牙龈出血风险因素得到控制之前,不应进行牙周治疗。
-
药物引起的牙龈增生—牙周管理与药物审查:由高血压治疗药物(如硝苯地平和氨氯地平)等几种药物引起的药物性牙龈增生,主要与不良口腔卫生和牙龈炎症有关。63,64 因为后者是可改变的因素,牙周治疗对于管理这一状况是有效的。当牙龈炎症主要通过NSPT的第1步和第2步得到控制后,剩余的过度生长牙龈组织应通过牙龈切除术(第3步手术)去除。65 累积证据表明,除非牙周治疗未能控制牙龈增生,否则不需要进行药物调整。66,67
治疗益处
牙周炎的管理已被证明可以改善内皮功能,这在一定程度上有助于控制CVD。例如,一项研究报道,在NSPT后6个月,可溶性E-选择素(一种重要的内皮激活标志物)的水平显著降低。68 牙周治疗已被发现通过减轻炎症和促进血糖控制来降低CVD的风险。69 最近的研究还发现,牙周治疗可以降低血压和C-反应蛋白水平。70 新型材料如集抗菌和抗炎功能于一体的双功能水凝胶平台,同时控制牙周炎和高血压正在被研究。71 然而,目前缺乏高质量的证据来评估牙周治疗在减少心血管事件发生或复发方面的益处。
骨质疏松
背景
Osteoporosis is a metabolic skeletal disorder featuring reduced bone mineral density and microarchitectural deterioration. As the elderly population increases, osteoporosis is regarded as a major health problem. The global prevalence of osteoporosis in elders was estimated as 21.7%, while the highest prevalence was found in Asia (24.3%).72 In China, 90 million people were estimated to suffer from osteoporosis.73 A link between low bone mineral density and more severe periodontitis has been observed in postmenopausal women, but the evidence from both individual studies and meta-analyses remains limited.74,75
Osteoporosis and periodontitis are both regarded as osteoimmune-related diseases, wherein immune cells modulate the activities of osteoclasts and osteoblasts.76 This osteoimmune imbalance is further accentuated by trained osteoclastogenesis, cellular senescence with its associated secretory phenotype, and signals from the oral-gut-bone axis, a process that exacerbates bone loss while compromising regenerative capacity.77,78,79
Clinically, antiresorptive agents (e.g., bisphosphonate and denosumab) and anabolic agents (e.g., teriparatide and romosozumab) are used to treat osteoporosis.80 However, long-term anti-resorptive therapy carries a risk of medication-related osteonecrosis of the jaw (MRONJ). MRONJ is a complication attributed to excessive suppression of bone turnover, reduced vascular perfusion, and impaired mucosal immune defense. It warrants particular attention in periodontal management.81,82
Clinical guidance recommendation
There is no specific contraindication to periodontal management in patients with osteoporosis. However, given the osteoporosis-related microenvironment that affects osteogenic activity, periodontal regenerative surgery becomes more challenging and requires careful evaluation.83 Meanwhile, clinicians should be aware of some special populations, such as postmenopausal women, the elderly, smokers, and people with obesity, who are prone to experience osteoporosis.84,85,86 The susceptibility to osteoporosis and the difficulties in alveolar bone regeneration should be emphasized to these people.
Pretreatment assessment
The medication history should be evaluated before treatment.
-
Type of antiresorptive agents: A recent retrospective cohort study utilizing the TriNetX global collaborative network found that denosumab was associated with the highest risk of MRONJ, followed by zoledronic acid, whereas ibandronate had the lowest risk.82 [C]
-
Treatment duration: Longer duration of antiresorptive therapy has been identified as a risk factor for MRONJ in patients with osteoporosis. Nevertheless, evidence regarding the precise threshold duration associated with elevated risk is currently inconsistent.87 [B]
-
Route of administration: Intravenous injection is more likely to cause MRONJ than oral administration.87 [B]
Risk stratification and treatment modification
Periodontal and peri-implant inflammation were considered important risk factors for MRONJ.88,89,90,91 Principles for periodontal management on antiresorptive therapy are discussed below (Fig. 4).
Decision-making chart for patients on antiresorptive therapy.80,81,87,95,151 MRONJ, medication-related osteonecrosis of the jaw
Before antiresorptive therapies
-
Given that long-term antiresorptive therapy increases the risk of MRONJ, which can be mitigated by good oral hygiene and periodontal health, periodontal treatment before initiating antiresorptive therapy is recommended to reduce MRONJ incidence.87 [B]
-
Antiresorptive therapy alone should not preclude implant placement in osteoporotic patients, as current evidence does not confirm a substantially increased MRONJ risk in this setting.92 [C]
During antiresorptive therapies
-
Generally, local therapies are considered safe during antiresorptive therapy in patients with nonmalignant diseases such as osteoporosis. Currently, drug holidays of antiresorptive agents for dentoalveolar surgeries remain controversial.87 [B]
-
It was recently found that periodontal management, especially during the first three years of antiresorptive therapy, is crucial for preventing peri-implantitis and thus reducing the risk of MRONJ-related implant failure.93 [C]
Clinical precautions
-
Long-term implant maintenance—patient education: To date, the role of antiresorptive therapies in implant failure among osteoporotic patients remains unclear.94 Nevertheless, patients with already-placed implants should be informed about the low risk of implant failure as well as the importance of long-term maintenance.87
-
MRONJ prevention—perioperative management and systemic risk modification: To reduce the risk of MRONJ induced by periodontal and implant therapy, perioperative antimicrobial prophylaxis, including systemic antibiotics and antimicrobial mouthwash before and after treatment, is recommended. At the same time, other risk factors for MRONJ should be modified, including diabetes control and smoking cessation.87
-
MRONJ treatment—surgical intervention and debridement: Although generally considered safe, periodontal therapy may carry a risk of MRONJ, as reported in a patient receiving denosumab who developed MRONJ after Steps 1 and 2 NSPT.95 For such circumstances, under the premise of systemic antibiotics and local antimicrobial treatment, related teeth should be extracted, and necrotic bone should be removed with complete debridement.95
-
Emerging locally bisphosphonate therapy—cautious evaluation: Intriguingly, the potential therapeutic role of locally administered bisphosphonates as small-molecule adjuncts in periodontal treatment is currently under investigation, and reported studies have demonstrated significant improvements in clinical parameters.96,97 However, considering the possible complications mentioned above, clinical application of such antiresorptive agents requires comprehensive evaluation.
Therapeutic benefits
Combined application of NSPT and metformin showed obvious improvement in systemic bone loss.84 Novel materials such as reactive oxygen species-responsive hydrogels have been investigated to function as anti-inflammatory and anti-oxidative agents in periodontitis-related osteoporosis.98,99 Treatment of osteoporosis was found to improve periodontal conditions, which is corroborated by the lower prevalence of severe periodontitis observed in treated patients compared to untreated ones.100
Respiratory diseases
Background
According to the GBD 2023 study, the global burden of chronic respiratory diseases continues to rise alongside population growth and aging, with an estimated 569.2 million prevalent cases and 4.2 million deaths worldwide in 2023.101 Chronic respiratory diseases rank as the third most common cause of mortality in China, with an estimated 1.33 million deaths each year.102
Growing data suggest the bidirectional relationships between periodontitis and respiratory diseases. To date, the risk of respiratory diseases has been found to be increased in patients with periodontitis, including community-acquired pneumonia (CAP),103 hospital-acquired pneumonia (HAP),104 chronic obstructive pulmonary disease (COPD),105,106 obstructive sleep apnea (OSA),107 lung abscess,108 and pulmonary fibrosis.109 COPD patients have a 35% higher prevalence of periodontitis than non-COPD controls, albeit based on low-quality evidence.110 The relationship between periodontitis and asthma remains controversial, although the application of adrenergic inhalers was found to increase the risk of periodontitis and its progression to advanced stages.111
Inflammation, poor oral hygiene, and the immunosuppressive effect of corticosteroids, which are used for certain types of respiratory diseases such as asthma, are considered respiratory-related stimulative factors of periodontitis.112 Patients with respiratory insufficiency often exhibit compensatory mouth breathing, leading to oral dryness and reduced self-cleaning capacity, which further exacerbates plaque accumulation and gingival inflammation.113 On the contrary, increased periodontal pathogens were not only found in subgingival plaque samples,114,115 but were also detected in lung tissues and associated tissue fluid in people with pulmonary diseases.108,116,117 It was recently reported that the translocated periodontal pathogens could activate alveolar epithelial cells and subsequently promote neutrophil chemotaxis, thereby exacerbating airway inflammation and lung function decline.118 Other possible mechanisms by which periodontal pathogens promote the progression of pulmonary diseases include dysregulating the composition and function of bacterial biofilms in the respiratory tract,119 weakening the biological function of pulmonary epithelial cells,120 and inducing increased mucous secretion in the respiratory system.121
Clinical guidance recommendation
Pretreatment assessment
For patients with respiratory diseases, close monitoring of the patient’s respiratory status is required during treatment. To rapidly identify high-risk patients, dentists should assess recent respiratory-related hospitalization or emergency department visits (e.g., within 3 months), current active respiratory infection (fever, cough, sputum production, wheezing), dyspnea at rest or on minimal exertion, and current medications, particularly inhaled agents, systemic corticosteroids, and anticoagulants.
-
For patients with pulmonary tuberculosis: Disease activity must be assessed prior to any intervention. Patients with active tuberculosis should first receive standardized anti-tuberculosis therapy until sputum bacteriological conversion is attained. Periodontal treatment may only be initiated when the disease is stable, sputum bacteriological results are consistently negative, and non-infectivity is confirmed by a specialist physician.122,123 [B]
Risk stratification and treatment modification
Treatment principles for various respiratory disorders should be followed during periodontal management.30,31 The following modifications to periodontal treatment protocols are stratified by disease type.
Infectious respiratory diseases
-
It is recommended to use antibacterial mouthwash before the procedure to reduce the risk of cross-infection and complications.124,125,126 [A]
-
Ultrasonic scaling and air polishing should be avoided to reduce the risk of aerosol transmission.127 [C]
-
Basic periodontal treatment should be delivered within an isolated setting equipped with strict respiratory isolation measures.128 [B]
COPD
-
Periodontal treatment should be performed gently in separate sessions.128 [B]
-
Treatment should be avoided during acute exacerbations and conducted only after the condition has been stable with confirmation by a respiratory physician. [C]
Asthma
-
Periodontal treatment for asthmatic patients should be conducted during periods of stable condition without signs of acute exacerbation, with avoidance of peak allergic seasons and disease fluctuation phases.129 [B]
-
Anesthetics containing high-concentration epinephrine and allergenic antibiotics should be strictly avoided.129 [B]
Clinical precautions
The following clinical precautions should be observed during periodontal care for patients with respiratory disorders.
-
Oral plaque control: Control of oral plaque is pivotal for inhibiting pneumonia progression.130 For elderly patients, those with neurological disease sequelae, and bedridden patients at risk of aspiration, oral hygiene should be optimized (e.g., chlorhexidine mouthwash administration) prior to invasive oral/periodontal procedures.131 Additionally, professional oral care, including cleaning of teeth, tongue surfaces, and dentures, can effectively reduce oropharyngeal microbial load, thereby mitigating the risk of aspiration pneumonia.132
-
Therapeutic positioning: For patients with respiratory failure, severe asthma, massive pleural effusion, or severe pulmonary arterial hypertension, all basic therapeutic procedures are to be performed gently to minimize airway irritation. A semi-recumbent or sitting position should be prioritized during dental treatment, and a fully supine position should be avoided to prevent postural dyspnea and hemodynamic fluctuations.
Therapeutic benefits
Periodontal treatment was considered positive in reducing the occurrence of respiratory infections such as HAP.133 Although evidence is limited, periodontal treatment was found to effectively improve COPD outcomes, including reducing exacerbations and slowing lung function decline.134 Similarly, in patients without overt pulmonary pathology, lung function was also improved following periodontal therapy.135 In addition, some patients with OSA who use oral appliances or continuous positive airway pressure masks may experience reduced comfort and compliance due to gingival swelling and pain when comorbid with periodontitis. Periodontal treatment can alleviate these symptoms and thereby improve comfort and adherence to OSA therapy, ultimately enhancing treatment outcomes.136
Liver diseases
Background
Liver diseases that are attributed to risk factors such as viral infection and excessive alcohol consumption remain a significant global burden. In 2021, chronic liver disorders affected approximately 1.7 billion individuals worldwide.137 In recent years, the widespread administration of hepatitis B vaccination has contributed to a marked decline in the prevalence of viral hepatitis. Nevertheless, the overall burden of liver diseases remains substantial, with metabolic dysfunction-associated steatotic liver disease (MASLD, the recent replacement term for non-alcoholic fatty liver disease (NAFLD)) emerging as the predominant form of chronic liver disease globally. According to GBD 2023 estimates, MASLD currently affects around 1.3 billion people.138 The latest meta-analysis reported a significant association between periodontitis and MASLD, with a stronger effect size when periodontitis was diagnosed by clinical attachment loss.139
Several mechanisms support the relationship between liver diseases and periodontitis, including systemic inflammation, the colonization of periodontal pathogens through systemic circulation, and oral-gut-liver regulation via gut microbiota and oxidative stress.140,141,142 Periodontitis-driven systemic inflammation can exacerbate hepatic insulin resistance and lipid dysregulation, establishing a metabolic inflammatory loop that links periodontal health to MASLD and its comorbidities (e.g., diabetes and CVDs).143,144
Clinical guidance recommendation
Pretreatment assessment
Owing to various characteristics of liver diseases, such as infectiousness, hemorrhage disorders, and immunosuppression, careful assessment should be taken before and during periodontal management.
-
Patients should be carefully inquired about a history of liver diseases at the first visit. Quantitative determination of HBV (hepatitis B virus)-DNA and HCV (hepatitis C virus)-RNA should be quantified for active hepatitis B and hepatitis C, respectively.145 [B]
-
Coagulation function should also be evaluated, and the treatment principles based on the platelet count are consistent with the abnormal coagulation function mentioned above (Fig. 3). [B]
Risk stratification and treatment modification
According to the patient’s hepatic status, the following modifications to periodontal treatment protocols are recommended.
-
Treatment timing in active viral hepatitis: Periodontal therapy, especially treatment with sonic instruments, should be postponed for patients with active infection of viral hepatitis.145 [B]
-
Treatment modification after transplantation therapy: For patients who have undergone liver transplantation, non-invasive treatments such as supragingival scaling (Step 1) are permissible after 3 months, whereas invasive interventions like subgingival instrumentation (Step 2) require consideration of prophylactic antibiotics even beyond 6 months post-transplantation.146,147 [B]
-
Implant surgery timing after transplantation therapy: To avoid the impact of decreased bone density induced by transplantation surgery, implant surgery should be postponed for at least 12 months.148,149 [C]
Clinical precautions
During periodontal care for patients with liver diseases, the following clinical precautions specific to periodontal procedures should be observed:
-
Cross-infection control: For some acute periodontal infections or persistent gingival bleeding, emergency treatment should be done under the standards for inhibition of cross-infections specific to infectious diseases.
-
Special care for implant surgery: Strict infection control and minimally invasive techniques are recommended to improve success rates and long-term efficacy.148
-
Medication management: Specifically for hepatic dysfunction, adjunctive medication for periodontal treatment should be fully evaluated, such as acetaminophen, tetracyclines, sulfonamides, and fluoroquinolones.30,150,151 Recently, probiotics, prebiotics, and bacteriocins are considered potentially alternative strategies.152
-
Drug-influenced gingival enlargement—surgical timing: Drug-influenced gingival enlargement is regarded as a side effect of immunosuppressive therapy. Step 3 periodontal surgery such as gingivectomy should be postponed until the gingival condition is stable.153
Therapeutic benefits
Despite limited evidence, periodontal therapy has been shown to improve liver disease status. For instance, PMPR was reported to decrease the level of alanine aminotransferase (ALT) and endotoxins in patients with NAFLD.154,155
Kidney diseases
Background
Chronic kidney disease (CKD) refers to the progressive degeneration of kidney function.156 Based on the latest GBD data, CKD is regarded as one of the major global health issues, with 788 million individuals living with CKD in 2023.157 Specific to China, the number of CKD incidence cases was estimated to be 156 million.158 Similar to liver diseases, kidney diseases are also complicated by some shared systemic conditions with periodontitis, such as diabetes and CVDs.156,159
CKD was reported to increase the prevalence of periodontitis.160 A recent cohort study further reported that stage IV periodontitis was independently associated with certain renal function indicators compared with Stage I/II.161 However, the contribution of periodontal infection to all-cause mortality in CKD patients remains to be established.162 Inflammation, oxidative stress, and metabolic derangements are among the putative mechanisms linking periodontitis to kidney diseases.163,164
Clinical guidance recommendation
Pretreatment assessment
For patients with CKD, laboratory parameters of renal function should be assessed prior to periodontal therapy. Given the associated coagulation impairment, platelet count and INR should also be evaluated. The treatment principles are consistent with those for coagulation disorders described above (Fig. 3). [B]
Risk stratification and treatment modification
For kidney transplantation cases, principles of periodontal and implant treatment are similar to patients receiving liver transplantation. Additional modifications to periodontal treatment protocols are recommended as follows.
-
Infection control and systemic benefits: From the perspective of infection control, periodontal therapy was found to be essential not only to improve concurrent diseases such as CVDs, but also to prevent complications induced by kidney transplantation.165,166 Therefore, periodontal treatment is recommended to be carried out prior to dialysis therapy. [C]
-
Medical clearance thresholds: When blood urea nitrogen is above 60 mg/dL and/or serum creatinine is above 1.5 mg/dL, periodontal therapy should be avoided.30 [B]
-
Timing around hemodialysis: It should be noted that special management should be taken in hemodialysis patients who are prone to have hepatitis, anemia, and prolonged hemorrhage. Importantly, periodontal treatment should be applied on the day after dialysis.30 [B]
Clinical precautions
Beyond the procedural modifications above, the following clinical precautions specific to periodontal care should be observed for patients with chronic kidney disease:
-
Raising awareness of periodontal therapy prior to dialysis: Following a comprehensive periodontal evaluation, clinical decision-making should balance infection control with tooth preservation. Although prophylactic extraction of mobile teeth prior to dialysis could minimize perioperative infection risk, this practice should not be applied indiscriminately. Teeth with a favorable prognosis should undergo sequential periodontal treatment in advance if systemic conditions permit, thereby preserving masticatory function and quality of life.167
-
Medication management: With the aim of reducing the metabolic burden on the kidneys, drugs such as phenacetin, tetracycline, and aminoglycoside antibiotics should be avoided. Local anesthesia with lidocaine is considered safe.30
-
Long-term monitoring: Periodontal examination is recommended every 3 to 6 months in patients with CKD.168
Therapeutic benefits
Periodontal treatment has been shown to partially alleviate CKD by reducing the burden of periodontal pathogens, suppressing systemic inflammation, and improving key renal function indicators following PMPR therapy.169,170,171
Cancer
Background
Cancer resulted in approximately 271 million disability-adjusted life-years (DALYs) in the whole world in 2023.172 In 2024, China recorded approximately 5.15 million new cancer cases, representing about 25% of the global total and ranking first in national cancer incidence worldwide.173 Advances in diagnostic and therapeutic technologies have reduced cancer mortality and improved cure rates, while also extending survival for advanced-stage patients. Consequently, the population of individuals with a history of cancer therapy has been steadily growing.
The relationship between periodontitis and certain types of cancer, such as head and neck cancer, digestive tract cancer, lung cancer, and breast cancer, has been studied in recent years. To date, the association between periodontitis and head and neck cancer is supported by the most substantial evidence.174 Dysbiosis of the oral microbiota and systemic inflammation were considered the major mechanisms that supported the association between periodontitis and cancer risk.175,176,177
Clinical guidance recommendation
Pretreatment assessment
-
The type, current phase, and therapeutic dose of oncologic therapy should be assessed. Primary radiation doses above 6000 centigrays (cGy) were associated with a significantly higher incidence of osteoradionecrosis (ORN).178,179,180 [B]
-
Medication history, especially the use of antiresorptive agents, should be carefully inquired.82 Treatment with zoledronate or denosumab for 2 years or longer was found to be associated with an increased risk of MRONJ and should be carefully considered.87 [B]
-
Close attention should be paid to coagulation function by evaluating correlated parameters30,59 (Fig. 3). [B]
Risk stratification and treatment modification
Several principles should be followed to avoid serious complications such as oral infection and ORN.30 To date, the role of pre-oncological periodontal therapy such as Steps 1 and 2 NSPT in oral mucositis remains controversial.181 According to the timeline of oncological therapies, the following modifications to periodontal treatment protocols are stratified as follows:
Before chemotherapy and radiotherapy
-
Uncontrolled periodontal conditions, especially stage Ⅲ–Ⅳ periodontitis, are considered risk factors for ORN.180,182 If tolerated, periodontal treatment should be performed to reduce oral bacterial load and facilitate ORN prevention.30,183 [B]
-
For symptomatic non-vital teeth, endodontic therapy should be completed no later than 7 days prior to the start of radiotherapy, whereas teeth with a poor prognosis should be extracted at least 14 days before radiotherapy.151 [B]
During chemotherapy and radiotherapy
-
Periodontal treatment can be safely performed when the white blood cell count is above 2000/mm3 with absolute neutrophil count (ANC) of 1000 to 1500/mm.3 It should ideally be scheduled on the day before the next chemotherapy cycle.30 [B]
-
During radiotherapy, oral examination is suggested to be conducted weekly to monitor the occurrence of oral mucositis, and periodontal scaling can be taken if clinically indicated.184 [B]
After chemotherapy and radiotherapy
-
Teeth with poor prognosis should not be extracted until at least 6 months after radiotherapy, except in rare circumstances.185 [B]
Before antiresorptive therapies
Cancer and chemotherapy are regarded as risk factors for MRONJ. Further, the dosing intensity and treatment duration of antiresorptive therapy for bone metastasis prevention are far greater than those in the osteoporotic setting. Thus, the risk of MRONJ is significantly higher in patients with malignancies than in those with osteoporosis. In addition, teeth with poor prognosis should also be extracted before antiresorptive therapy.87 [B]
During antiresorptive therapies
-
Oral treatments should be performed with caution during this phase. Tooth extraction, implant surgery, and other dentoalveolar surgeries should be avoided and, where appropriate, replaced with nonsurgical endodontic therapy.151 [B]
-
As in patients with osteoporosis undergoing antiresorptive therapy, drug holidays in patients with malignancies remain controversial87 (Fig. 4). [B]
Clinical precautions
Beyond the procedural modifications above, the following clinical precautions for long-term oral care should be observed for patients who have undergone radiotherapy:
During the first 2–5 years following radiotherapy, when the risk of ORN increases, oral hygiene is particularly important. Chlorhexidine rinses were found beneficial in patients after radiotherapy.186 Meanwhile, regular recall is recommended for long-term management.30,187
Hematological disorders
Background
Hematological disorders refer to a series of complicated blood dysfunctions, such as anemia, leukemia, hemophilia, and agranulocytosis. Accumulating clinical evidence is revealing the potential relationships between hematological disorders and periodontitis.188,189,190,191 Based on a recent experimental study, ligature-induced periodontitis was shown to promote clonal hematopoiesis, a finding that supports a potential mechanistic link between periodontitis and other hematological disorders.192
Manifestations in the gingival tissues, such as a pale and vulnerable appearance, bleeding tendency, gingival overgrowth, and recurrent ulceration, can frequently be the early symptoms of some hematologic diseases.193 Moreover, during periodontal therapy, unrecognized or acute hematological disorders might cause serious complications such as infection of the deep periodontal tissues, post-treatment bleeding, or other life-threatening conditions.194 Therefore, dentists need to be vigilant about the associated oral manifestations and be familiar with the treatment principles for such conditions.
Clinical guidance recommendation
Pretreatment assessment
A comprehensive medical inquiry about history of bleeding following previous injury or surgery is essential to identify hematological conditions or detect potential disorders. For these patients, consultation with a hematologist should be sought from the outset of periodontal management.30 [B]
Risk stratification and treatment modification
The following periodontal procedural modifications are recommended according to different types of hematological disorders.30
Anemia
Hemoglobin (Hb) and Oxygen saturation (SpO2) require close monitoring. Hb < 11 g/dL and SpO2 < 91% indicate unstable conditions in which periodontal therapy should be postponed. Conversely, periodontal treatment can be performed under strict infection control.195 [B]
Agranulocytosis
Hematologists should be consulted, and Steps 1 and 2 NSPT under antibiotic protection can be performed during the remission period.30 [B]
Clinical precautions
For the hematological conditions below, the focus is systemic evaluation and risk control, which should guide the safety, timing, and extent of any necessary periodontal treatment.
Anemia
For some severe types of anemia, such as aplastic anemia, a systematic evaluation of blood parameters and overall systemic conditions should be undertaken before non-surgical or even surgical periodontal treatment.30
Leukemia
For patients with leukemia, special attention should be paid to their high susceptibility to infection, bleeding tendency, and the systemic impact of chemotherapy.
-
ANC should be closely monitored. It is considered a high risk of infection when ANC is below 1 000 per mm3, and antibiotics should be applied before periodontal therapy.59
-
For necessary treatment, platelet transfusion might be applied in advance when platelet counts are below 50 × 109 per L196 (Fig. 3).
-
Considerations for chemotherapy should follow the recommendations for patients with cancer outlined above.
Hemophilia
-
For patients with hemophilia who have abnormal coagulation function and obvious bleeding tendency, Steps 1 and 2 NSPT are more recommended compared to Step 3 periodontal surgery.
-
For Step 3 periodontal surgery, INR should be less than 2–2.5, and the platelet count should be more than 80 × 109 per L. If necessary, antifibrinolytic agents such as local use of tranexamic acid might be applied to prevent peri-treatment bleeding.197
Therapeutic benefits
Periodontal treatments have been proved to be effective on certain types of hematological disorders. From the aspect of inflammation control, NSPT was found to increase the level of Hb in patients with periodontitis who had the tendency of anemia of inflammation.188 For patients with aplastic anemia, NSPT was found to effectively reduce cyclosporine-influenced gingival enlargement with regular return visits and antibiotic protection.198
Conditions with abnormal hormone levels
Abnormal levels of sex steroid hormones
Background
Serving as target sites of sex steroid hormones, periodontal tissues are prone to be affected when sex steroid hormones remain abnormal. Variations in sex hormone levels are closely linked to the severity, progression, and therapeutic outcomes of periodontal diseases by modulating the inflammatory response of periodontal tissues to dental plaque biofilm.26,199
Clinical guidance recommendation
Pretreatment assessment
A specific pretreatment evaluation is required for pregnant patients undergoing periodontal therapy, including precise gestational stage to determine the relatively safe treatment window as well as the necessity of periodontal therapy.30 [B]
Risk stratification and treatment modification
For periodontal patients with abnormal sex hormone levels, extreme caution is advised when performing periodontal therapy during pregnancy.
-
During the first trimester of gestation period: Dental radiography as well as elective mechanical and drug therapy need to be avoided.30 [B]
-
During the second trimester of the gestation period: Step 3 periodontal surgery is suggested to be postponed until after delivery. However, for some emergencies such as pregnancy epulis which cause difficulty in mastication or persistent gingival bleeding, gingivectomy can be carried out.30 [B]
Clinical precautions
Periodontal management should be adjusted in response to the regulation of sex steroid hormones during different physiological cycles.30,200
Puberty
Adolescents usually exhibit heightened gingival sensitivity to plaque accumulation. Steps 1 and 2 NSPT are essential to remove plaque stimulation, which will control gingival inflammation. For the remaining overgrown gingival tissue as well as fibrous hyperplasia, gingivectomy and gingivoplasty (Step 3) can be performed. It should be emphasized that good oral hygiene and regular PMPR (Step 1) are necessary for adolescents, especially before and during orthodontic treatment.
Menstrual period
The menstrual period is not considered a contraindication to periodontal therapy. Necessary treatment can be safely performed provided that pain management, infection prevention, and control of excessive gingival bleeding are ensured.
Preconception period
Women in the preconception period should be educated about the importance and necessity of periodontal health since the progression or severity of gingival inflammation as the fluctuation of hormones in the gestation period, is closely related to periodontal status before pregnancy. Meanwhile, Steps 1 and 2 NSPT, as well as necessary surgical treatment (Step 3) need to be carried out.
Gestation period
-
The first trimester: Periodontal treatment during the first trimester should be performed with extreme prudence.
-
The second trimester: The second trimester is regarded as a relatively safe period, during which routine dental care such as Step 1 PMPR can be performed to control active infection. Though not recommended, necessary dental radiographs (e.g., bitewing, panoramic, or selected periapical films) can be taken under the protection of lead aprons. For acute inflammatory conditions, such as periodontal abscesses, necessary medications can be used, provided that their potential side effects on both the pregnant woman and the fetus are fully considered.
-
The third trimester: For the reason that the uterus is sensitive to mechanical stimuli, periodontal treatment should also be performed prudently, especially in the last half of the third trimester to prevent preterm delivery. Meanwhile, attention should be paid to supine hypotensive syndrome.
-
Lactation period: Periodontal therapy is considered safe after birth-delivery. For essential drug therapy, the prescribed drugs need to be taken just after breastfeeding and sustained for at least 4 h before the next feeding.
Thyroid disorders
Background
The thyroid is the largest endocrine gland with multiple functions in physiological regulation. Thyroid disorders mainly include functional disorders (e.g., hypothyroidism and hyperthyroidism), structural disorders (e.g., thyroid nodules), thyroiditis (e.g., Hashimoto’s thyroiditis), and thyroid tumors. Nowadays, more and more people suffer from thyroid disorders, and thyroid cancer has become the most common endocrine malignancy worldwide.201 In China, the cases of thyroid cancer per 100 000 people in 1990 were 0.87, while the data significantly increased to 3.88 in 2021. High BMI was found to be a major risk factor for thyroid cancer in China.202
Despite the insufficient clinical evidence, the potential relationship between periodontitis and thyroid dysfunction has been revealed.203 It was recently found that the prevalence and severity of periodontitis were increased in patients with autoimmune hypothyroidism, and thyroid parameters such as thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4) were positively associated with periodontal parameters.204 Moreover, TSH might be applied as a potential predictor for periodontitis.205 Generally, systemic inflammation and abnormal bone metabolism are considered the major mechanisms related to the association between periodontitis and thyroid disorders.206,207
Clinical guidance recommendation
Pretreatment assessment
For patients with thyroid disorders, the stability of thyroid parameters such as TSH, T3, and T4 should be evaluated.30 [B]
Risk stratification and treatment modification
Based on the above assessment, the following periodontal procedural considerations apply:
-
Periodontal treatment is generally considered safe for individuals with thyroid disorders.30 [B]
-
Periodontal therapy should be deferred for patients with uncontrolled thyrotoxicosis.30 [B]
Clinical precautions
Medication considerations: Due to thyroid dysfunction, certain medicines need to be carefully applied during periodontal therapy. For patients with thyrotoxicosis or poorly controlled thyroid disorders, vasopressor amines such as epinephrine should be avoided. For patients with hyperthyroidism, the dosage of these medicines needs to be evaluated to prevent possible cardiovascular disorders, such as increased cardiac output and myocardial ischemia.30
Therapeutic benefits
The positive role of periodontal therapy in thyroid disorders has been reported by limited studies. In hypothyroid patients with periodontitis, the level of TSH was significantly reduced after 3 months following NSPT.208 More clinical studies are needed to explore the effect of periodontal therapy on the regulation of thyroid function.
Conclusions and future perspectives
In conclusion, this expert consensus reframes periodontitis management for medically complex patients as a dynamic, risk-stratified process that is tightly aligned with the individual’s medical status and treatment course. At its core, from initial debridement to surgical planning, clinical decision-making hinges on a baseline safety appraisal encompassing hemorrhagic risk, immune competence, and major organ reserve (i.e., metabolic, excretory, hemodynamic, and skeletal remodeling capacities), since these domains collectively define the risk assessment for dental intervention. Accordingly, the proposed strategy adopts a sequenced approach to treatment planning: non-surgical therapy proceeds with routine mechanical measures, coupled with dose vigilance for any adjunctive drugs according to organ function, whereas surgical phases are intentionally postponed until medical stability is formally confirmed. Equally importantly, the long-term supportive care plan has been shifted from fixed-interval recall to adaptive recall intervals, with re-evaluation prompted by any significant change in the patient’s comorbidity status or medication profile. Taken together, these practical principles constitute a pragmatic, safety-oriented framework that prioritizes patient stability over procedural convenience.
Future research should address several priorities. First, epidemiological evidence remains incomplete for certain periodontitis–systemic disease associations, warranting large-scale studies with rigorous phenotyping. Second, clinical decision-making for patients with systemic conditions relies largely on observational studies of low evidentiary strength; well-powered randomized trials, pragmatic multi-center designs, and condition-specific registries are therefore urgently needed. Third, chairside biomarker testing capable of monitoring both oral and systemic disease activity warrants prospective validation to support more tailored clinical decisions. Until such evidence emerges, this consensus recommends that clinical decisions be individualized through close dental–medical collaboration and careful systemic risk assessment. Bridging these gaps will require sustained interdisciplinary effort, but the principles outlined here offer a practical framework for care in the interim.
References
Nascimento, G. G., Alves-Costa, S. & Romandini, M. Burden of severe periodontitis and edentulism in 2021, with projections up to 2050: The Global Burden of Disease 2021 study. J. Periodontal Res. 59, 823–867 (2024).
Zhang, K., Ma, Y., Shi, J. & Geng, Y. Epidemiological trends and incidence prediction of periodontal disease based on the Global Burden of Disease study 2021. Front. Dent. Med. 6, 1643049 (2025).
Zhou, M. et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 394, 1145–1158 (2019).
The Global Burden of Disease, Injury and Risk Factor Collaborators Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1873–1922 (2025).
Romandini, M., Hajishengallis, G., Curtis, M. & Baima, G. Periodontal medicine rewired: mechanisms linking periodontitis to systemic diseases. J. Periodontal Res. 0, 1–42 (2026).
Loos, B. G. & Van Dyke, T. E. The role of inflammation and genetics in periodontal disease. Periodontology 83, 26–39 (2020).
Villoria, G. E. M., Fischer, R. G., Tinoco, E. M. B., Meyle, J. & Loos, B. G. Periodontal disease: a systemic condition. Periodontology 96, 7–19 (2024).
Tonetti, M. S., Jepsen, S., Jin, L. & Otomo-Corgel, J. Impact of the global burden of periodontal diseases on health, nutrition and wellbeing of mankind: a call for global action. J. Clin. Periodontol. 44, 456–462 (2017).
Li, X. et al. Maladaptive innate immune training of myelopoiesis links inflammatory comorbidities. Cell 185, 1709–1727.e1718 (2022).
Jin, W. et al. The oral - X axis: from periodontal dysbiosis to systemic disease. Front. Immunol. 17, 1806445 (2026).
Romandini, M. et al. Periodontitis, edentulism, and risk of mortality: a systematic review with meta-analyses. J. Dent. Res. 100, 37–49 (2021).
Marruganti, C., Suvan, J. E. & D’Aiuto, F. Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity. Periodontology 2000 00, 1–16 (2023).
Juni, P. et al. 2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention. Eur. Heart J. 46, 1885–1894 (2025).
van der Wal, H. et al. Development of a set of patient-centred outcome measures for patients with major injury: Delphi-based consensus recommendations from the International Consortium for Health Outcomes Measurement Major Injury Working Group. EClinicalMedicine 90, 103617 (2025).
Sanz, M. et al. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. J. Clin. Periodontol. 45, 138–149 (2018).
Chinese Stomatological, A. [Consensus of Chinese stomatological multidisciplinary experts on maintaining periodontal health (First edition)]. Zhonghua Kou Qiang Yi Xue Za Zhi 56, 127–135 (2021).
Genitsaridi, I. et al. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diab Endocrinol. 14, 149–156 (2026).
Deng, W. et al. National burden and risk factors of diabetes mellitus in China from 1990 to 2021: Results from the Global Burden of Disease study 2021. J. Diab 16, e70012 (2024).
Wang, L. et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317, 2515–2523 (2017).
Wang, L. et al. Prevalence and Treatment of Diabetes in China, 2013-2018. JAMA 326, 2498–2506 (2021).
Papapanou, P. N. et al. Periodontitis: consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J. Clin. Periodontol. 45, S162–S170 (2018).
Botelho, J. et al. Oral health and diabetes: a systematic review and meta-analysis. Lancet Public Health 11, e555-e566 (2026).
Edgar, L. et al. Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis. Circulation 144, 961–982 (2021).
Barutta, F., Bellini, S., Durazzo, M. & Gruden, G. Novel insight into the mechanisms of the bidirectional relationship between diabetes and periodontitis. Biomedicines 10, 178 (2022).
Zhu, Y. et al. The role of PKM2-mediated metabolic reprogramming in the osteogenic differentiation of BMSCs under diabetic periodontitis conditions. Stem Cell Res. Ther. 16, 186 (2025).
Sanz, M. et al. Treatment of stage I-III periodontitis-the EFP S3 level clinical practice guideline. J. Clin. Periodontol. 47, 4–60 (2020).
Society, C. D. Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition). Chin. J. Diab Mellit. 17, 16–139 (2025).
Yan, F. & Chen, F. Periodontology, 6th edn (People’s Medical Publishing House, 2025).
Graziani, F. et al. Acute-phase response following one-stage full-mouth versus quadrant non-surgical periodontal treatment in subjects with comorbid type 2 diabetes: a randomized clinical trial. J. Clin. Periodontol. 50, 487–499 (2023).
Michael G. Newman, P. R. K., Satheesh Elangovan, Yvonne Kapila. Newman and Carranza’s Clinical Periodontology and Implantology, 14th edn (Saunders Elsevier, 2023).
Herrera, D. et al. Association between periodontal diseases and cardiovascular diseases, diabetes and respiratory diseases: Consensus report of the Joint Workshop by the European Federation of Periodontology (EFP) and the European arm of the World Organization of Family Doctors (WONCA Europe). J. Clin. Periodontol. 50, 819–841 (2023).
Askar, H. et al. Incidence and severity of postoperative complications following oral, periodontal, and implant surgeries: a retrospective study. J. Periodontol. 90, 1270–1278 (2019).
Al-Abbadi, R., Shemais, N., Nawwar, A. & Fawzy El-Sayed, K. M. Non-surgical periodontal therapy with and without hyaluronic acid gel in type 2 diabetic stage-II periodontitis patients: a randomized clinical trial. BMC Oral. Health 25, 1166 (2025).
Yuqi, W., Hangying, X., Ruyi, Y., Xiaolan, Z. & Yajing, C. Effectiveness of probiotic therapy as an adjunct in the management of periodontal disease in type 2 diabetics: a systematic review and meta-analysis. Diab Res Clin. Pr. 226, 112358 (2025).
Xu, X. et al. Potential short-term shift in oral microbiota of patients with stage III-IV periodontitis and type 2 diabetes treated by non-surgical periodontal therapy. J. Dent. Sci. 20, 1470–1479 (2025).
D’Aiuto, F. et al. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diab Endocrinol. 6, 954–965 (2018).
Raedel, M., Noack, B., Priess, H. W., Bohm, S. & Walter, M. H. Massive data analyses show negative impact of type 1 and 2 diabetes on the outcome of periodontal treatment. Clin. Oral. Investig. 25, 2037–2043 (2021).
Ren, L., Fu, Y., Deng, Y., Qi, L. & Jin, L. Advanced glycation end products inhibit the expression of collagens type I and III by human gingival fibroblasts. J. Periodontol. 80, 1166–1173 (2009).
Zhao, P. et al. Hyperglycaemia-associated macrophage pyroptosis accelerates periodontal inflamm-aging. J. Clin. Periodontol. 48, 1379–1392 (2021).
Zhang, M. et al. Photoacoustic imaging-guided self-adaptive hyperthermia supramolecular cascade nano-reactor for diabetic periodontal bone regeneration. Adv. Sci. (Weinh.) 11, e2404143 (2024).
Xiang, D. D. et al. Diabetes and periodontitis: the role of a high-glucose microenvironment in periodontal tissue cells and corresponding therapeutic strategies. Stem Cell Res. Ther. 16, 366 (2025).
Duman, I., Tanriverdi, G. & Ozturk Ozener, H. Effects of vitamin K2 administration on guided bone regeneration in diabetic rats. J. Periodontal Res. 59, 993–1004 (2024).
Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. J. Am. Coll. Cardiol. 86, 2167–2243 (2025).
In China, T. & Hu, S. S. Report on cardiovascular health and diseases in China 2021: an updated summary. J. Geriatr. Cardiol. 20, 399–430 (2023).
Alam, M. K. et al. Periodontitis as an independent risk factor for cardiovascular disease: a systematic review and meta-analysis. BMC Oral Health 26, 1783 (2026).
Wang, J. et al. Hypertensive patients with periodontitis as predictors of cardiovascular and all-cause mortality: a long-term cohort study. Clin. Oral. Investig. 28, 582 (2024).
Wu, Y. et al. Alterations in the salivary microbiome and metabolism in patients with carotid atherosclerosis from rural Northeast China. J. Am. Heart Assoc. 13, e034014 (2024).
Xu, T. et al. Porphyromonas gingivalis infection promotes mitochondrial dysfunction through Drp1-dependent mitochondrial fission in endothelial cells. Int J. Oral Sci. 13, 28 (2021).
Herrera, D., Molina, A., Buhlin, K. & Klinge, B. Periodontal diseases and association with atherosclerotic disease. Periodontology 83, 66–89 (2020).
Mitroulis, I., Hajishengallis, G. & Chavakis, T. Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities. Cardiovasc. Res. 119, 2801–2812 (2024).
Ishai, A. et al. Periodontal disease associates with arterial inflammation via potentiation of a hematopoietic-arterial axis. JACC Cardiovasc. Imaging 12, 2271–2273 (2019).
Li, E., Huang, J., Yao, J., Lei, M. & Wu, M. Oral microbiota dysbiosis and the oral-X axis in chronic diseases. Genes Diseases 102274 https://doi.org/10.1016/j.gendis.2026.102274 (2026).
Chinese Society of Cardiology, C. M. A., Hypertension Committee of Cross-Straits Medicine Exchange, A., Cardiovascular Disease, P. & Rehabilitation Committee, C. A. o. R. M. [Clinical practice guidelines for the management of hypertension in China]. Zhonghua Xin Xue Guan Bing Za Zhi 52, 985–1032 (2024).
Song, J.-C. et al. Chinese expert consensus on standardized assessment of severe coagulopathy (2025 edition). Med. J. Chin. People’s Lib. Army 50, 1055–1069 (2025).
Sanz, M. et al. Periodontitis and cardiovascular diseases: Consensus report. J. Clin. Periodontol. 47, 268–288 (2020).
Orlandi, M., Graziani, F. & D’Aiuto, F. Periodontal therapy and cardiovascular risk. Periodontology 83, 107–124 (2020).
Lombardi, N., Varoni, E. M., Sorrentino, D. & Lodi, G. International normalized ratio (INR) values in patients receiving oral vitamin K antagonists and undergoing oral surgery: a clinical audit. Spec. Care Dent. 40, 374–381 (2020).
Chinese Society of Emergency Medicine (CSEM), Chinese Medical Doctors Association of Interventional, D., Hemorrhage Professional Committee of Chinese Research Hospital, A. & Chinese Federation of the Hemorrhage, C. [Expert consensus on critical values of hemorrhagic diseases (2023 version)]. Zhonghua Nei Ke Za Zhi 62, 939–948 (2023).
Mealey, B. L. Periodontal implications: medically compromised patients. Ann. Periodontol. 1, 256–321 (1996).
Wilson, W. R. et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the american heart association. Circulation 143, e963–e978 (2021).
Delgado, V. et al. 2023 ESC Guidelines for the management of endocarditis. Eur. Heart J. 44, 3948–4042 (2023).
Iijima, Y. et al. Persistent gingival bleeding related to periodontal disease. Cureus 17, e77693 (2025).
Drozdzik, A. & Drozdzik, M. Drug-induced gingival overgrowth-molecular aspects of drug actions. Int. J. Mol. Sci. 24, 5448 (2023).
Seymour, R. A., Ellis, J. S. & Thomason, J. M. Risk factors for drug-induced gingival overgrowth. J. Clin. Periodontol. 27, 217–223 (2000).
Mavrogiannis, M., Ellis, J. S., Seymour, R. A. & Thomason, J. M. The efficacy of three different surgical techniques in the management of drug-induced gingival overgrowth. J. Clin. Periodontol. 33, 677–682 (2006).
Ikawa, K., Ikawa, M., Shimauchi, H., Iwakura, M. & Sakamoto, S. Treatment of gingival overgrowth induced by manidipine administration. A case report. J. Periodontol. 73, 115–122 (2002).
Morikawa, S., Nasu, M., Miyashita, Y. & Nakagawa, T. Treatment of calcium channel blocker-induced gingival overgrowth without modifying medication. BMJ Case Rep. 14, e238872 (2021).
Tonetti, M. S. et al. Treatment of periodontitis and endothelial function. N. Engl. J. Med. 356, 911–920 (2007).
Bechina, C. et al. Effects of periodontal therapy on cardiovascular risk biomarkers: a systematic review. Oral. Health Prev. Dent. 23, 457–467 (2025).
Gandhi, K. K., Batra, C. & Affendi, H. Cardiovascular and anti-inflammatory effects of periodontal therapy: a systematic review and meta-analysis of randomized trials. J. Periodontol. 1–24 (2026). (Online ahead of print).
Xu, S. et al. Alleviate periodontitis and its comorbidity hypertension using a nanoparticle-embedded functional hydrogel system. Adv. Health Mater. 12, e2203337 (2023).
Salari, N. et al. Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J. Orthop. Surg. Res. 16, 669 (2021).
Wang, L. et al. Prevalence of osteoporosis and fracture in China: the China osteoporosis prevalence study. JAMA Netw. Open 4, e2121106 (2021).
Penoni, D. C. et al. Bone density and clinical periodontal attachment in postmenopausal women: a systematic review and meta-analysis. J. Dent. Res. 96, 261–269 (2017).
Joseph, B. et al. Low bone density and periodontal disease in postmenopausal women: a systematic review and meta-analysis. J. Fam. Med. Prim. Care 14, 4955–4966 (2025).
Chang, J., Bhuvanagiri, G. M., Dulkanchainun, M. & Wang, C. Osteoporosis and periodontitis: two-way epidemiological and mechanistic evidence. J. Periodontal. Res. 0, 1–29 (2026).
Haacke, N. et al. Innate immune training of osteoclastogenesis promotes inflammatory bone loss in mice. Dev. Cell 60, 1854–1870.e1856 (2025).
Yu, B. & Wang, C. Y. Osteoporosis and periodontal diseases - an update on their association and mechanistic links. Periodontology 89, 99–113 (2022).
Wang, N. et al. Periodontitis-associated salivary microbiota exacerbates systemic osteoclastogenesis via gut modulation and tryptophan metabolism suppression in ovariectomized mice. Int J. Oral Sci. 18, 14 (2026).
Omelchenko, V. et al. Modern strategies for osteoporosis therapy: current status and prospects for targeted intervention. Int. J. Mol. Sci. 26, 11092 (2025).
Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral. Maxillofac. Surg. 72, 1938–1956 (2014).
Chen, T. Y. et al. Medication-related osteonecrosis of the jaw following osteoporosis therapy: a real-world retrospective cohort study using the TriNetX global collaborative network. Bone 202, 117678 (2026).
Hu, H. T. et al. Emerging regulated cell death mechanisms in bone remodeling: decoding ferroptosis, cuproptosis, disulfidptosis, and PANoptosis as therapeutic targets for skeletal disorders. Cell Death Discov. 11, 335 (2025).
Chen, R. et al. Non-surgical periodontal therapy and metformin improve bone loss in obese mice with periodontitis by modulating the gut microbiota. FASEB J. 39, e70814 (2025).
Snyder, S. Postmenopausal osteoporosis. N. Engl. J. Med. 390, 675–676 (2024).
Morin, S. N., Leslie, W. D. & Schousboe, J. T. Osteoporosis: a review. JAMA 334, 894–907 (2025).
Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update. J. Oral. Maxillofac. Surg. 80, 920–943 (2022).
Wick, A. et al. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. Clin. Oral. Investig. 26, 2839–2852 (2022).
Lorenzo-Pouso, A. I. et al. Association between periodontitis and medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J. Oral. Pathol. Med. 49, 190–200 (2020).
Troeltzsch, M. et al. Chronic periodontal infection and not iatrogenic interference is the trigger of medication-related osteonecrosis of the jaw: insights from a large animal study (PerioBRONJ Pig Model). Medicina 59, 1000 (2023).
Bujila, A. et al. Peri-implant inflammation increases the risk of osteonecrosis in mice treated with bisphosphonate. J. Periodontol. 96, 894–905 (2025).
Ali, D. S. et al. Antiresorptive therapy to reduce fracture risk and effects on dental implant outcomes in patients with osteoporosis: a systematic review and osteonecrosis of the jaw taskforce consensus statement. Endocr. Pr. 31, 686–698 (2025).
Li, J. T. W. & Leung, Y. Y. Effect of antiresorptive drugs on osseointegrated dental implants: a systematic review. J. Clin. Med. 13, 2091 (2024).
Pruthi, G. Risk of medication-related osteonecrosis of the jaws (MRONJ) in osteoporotic patients treated with antiresorptive drug therapy and dental implants. Evid. Based Dent. 27, 46–48 (2026).
Diniz-Freitas, M., Fernandez-Feijoo, J., Diz Dios, P., Pousa, X. & Limeres, J. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: a case report. J. Clin. Periodontol. 45, 570–577 (2018).
Miron, R. J. et al. Autogenous platelet concentrates for treatment of intrabony defects-a systematic review with meta-analysis. Periodontol 2000 97, 153–190 (2025).
Miron, R. J. et al. Periodontal regeneration using platelet-rich fibrin. Furcation defects: a systematic review with meta-analysis. Periodontol 2000 97, 191–214 (2025).
Zhao, Y., Lan, W., Zhang, L., Xu, D. & Wang, C. Research progress on ROS-responsive hydrogels for the treatment of osteoporosis: a review. Biomed. Mater. 21, 022007 (2026).
Zhu, Y. et al. Injectable hydrogels with ROS-triggered drug release enable the co-delivery of antibacterial agent and anti-inflammatory nanoparticle for periodontitis treatment. J. Nanobiotechnol. 23, 205 (2025).
Passos-Soares, J. S. et al. Association between osteoporosis treatment and severe periodontitis in postmenopausal women. Menopause 24, 789–795 (2017).
Oh, J. et al. Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990-2023: a Global Burden of Disease study. Nat. Med. 32, 197–223 (2026).
Yin, Y., Lin, X., Zhong, W., Chen, T. & Chen, J. Burden of chronic respiratory disease in Fujian province, 1990-2021. PLoS ONE 20, e0335352 (2025).
de Melo Neto, J. P. et al. Periodontal infections and community-acquired pneumonia: a case-control study. Eur. J. Clin. Microbiol. Infect. Dis. 32, 27–32 (2013).
Gomes-Filho, I. S. et al. Influence of periodontitis in the development of nosocomial pneumonia: a case control study. J. Periodontol. 85, e82–90 (2014).
Scannapieco, F. A. & Ho, A. W. Potential associations between chronic respiratory disease and periodontal disease: analysis of National Health and Nutrition Examination Survey III. J. Periodontol. 72, 50–56 (2001).
Prasanna, S. J. Causal relationship between periodontitis and chronic obstructive pulmonary disease. J. Indian Soc. Periodontol. 15, 359–365 (2011).
Bianchi, E. et al. Relationship between periodontal disease and obstructive sleep apnea in adults: a systematic review. Dent. Res J. 21, 15 (2024).
Chen, X., Wu, L., Wu, R. & Dong, J. A pulmonary abscess caused by Porphyromonas gingivalis infection: a case report and literature review. Clin. Respir. J. 19, e70099 (2025).
Ye, H. L. et al. Periodontitis aggravates pulmonary fibrosis by Porphyromonas gingivalis-promoted infiltration of neutrophils and Th17 cells. Front. Cell Infect. Microbiol. 15, 1595500 (2025).
Sivaramakrishnan, G. & Sridharan, K. Linking lungs and gums: a meta-analysis of periodontitis prevalence and severity in chronic obstructive pulmonary disease. BDJ Open 12, 16 (2026).
Saleh, M. H. A. et al. Association between asthma and periodontitis: a case-control analysis of risk factors, related medications, and allergic responses. J. Periodontal Res. 60, 44–54 (2025).
Scannapieco, F. A. Poor oral health in the etiology and prevention of aspiration pneumonia. Clin. Geriatr. Med. 39, 257–271 (2023).
Herrera, D. et al. Periodontal diseases and cardiovascular diseases, diabetes, and respiratory diseases: Summary of the consensus report by the European Federation of Periodontology and WONCA Europe. Eur. J. Gen. Pr. 30, 2320120 (2024).
Tan, L., Tang, X., Pan, C., Wang, H. & Pan, Y. Relationship among clinical periodontal, microbiologic parameters and lung function in participants with chronic obstructive pulmonary disease. J. Periodontol. 90, 134–140 (2019).
Pinto, G. R. et al. Subgingival biofilm microbiome in individuals with asthma and periodontitis: Metagenomic analysis. Oral. Dis. 30, 4721–4730 (2024).
Nagaoka, K. et al. Quantitative detection of periodontopathic bacteria in lower respiratory tract specimens by real-time PCR. J. Infect. Chemother. 23, 69–73 (2017).
Guo, N. et al. Metagenomic next-generation sequencing reveals porphyromonas gingivalis in geriatric severe pneumonia complicated by empyema: case report. Infect. Drug Resist. 18, 4811–4816 (2025).
Zhang, L. et al. Periodontitis pathogen Porphyromonas gingivalis promotes chronic obstructive pulmonary disease via affecting neutrophils chemotaxis and function. Int J. Oral. Sci. 18, 4 (2026).
Li, Q. et al. Fusobacterium nucleatum interaction with Pseudomonas aeruginosa induces biofilm-associated antibiotic tolerance via Fusobacterium adhesin A. ACS Infect. Dis. 6, 1686–1696 (2020).
Zhao, Q. et al. Porphyromonas gingivalis inducing autophagy-related biological dysfunction in alveolar epithelial cells: an in vitro study. BMC Oral. Health 24, 1478 (2024).
Miya, C. et al. Porphyromonas gingivalis gingipains potentially affect MUC5AC gene expression and protein levels in respiratory epithelial cells. FEBS Open Biol. 11, 446–455 (2021).
Clinical Research Center for Infectious Disease, the Third People's Hospital of Shenzhen, Editorial Board of Chinese Journal of Antituberculosis National Expert consensus on a standard of activity judgment of pulmonary tuberculosis and its clinical implementation. Chin. J. Antituberc. 42, 301–307 (2020).
Cleveland, J. L., Robison, V. A. & Panlilio, A. L. Tuberculosis epidemiology, diagnosis and infection control recommendations for dental settings: an update on the Centers for Disease Control and Prevention guidelines. J. Am. Dent. Assoc. 140, 1092–1099 (2009).
Koletsi, D., Belibasakis, G. N. & Eliades, T. Interventions to reduce aerosolized microbes in dental practice: a systematic review with network meta-analysis of randomized controlled trials. J. Dent. Res. 99, 1228–1238 (2020).
Zhou, Q. et al. Comparative efficacy of preprocedural mouthwashes in reducing microbial aerosols during dental procedures: a network meta-analysis. Infect. Dis. Health 31, 100426 (2026).
Saini, R. S., Binduhayyim, R. I. H., Mosaddad, S. A. & Heboyan, A. Strategies for preventing aerosol-generated microbial contamination in dental procedures: a systematic review and meta-analysis. Am. J. Infect. Control 53, 638–647 (2025).
Goncalves Lomardo, P. et al. Concern about the risk of aerosol contamination from ultrasonic scaler: a systematic review and meta-analysis. BMC Oral. Health 24, 417 (2024).
Wang, Z. M. et al. Consensus of experts on the oral health management and medical risk prevention for the patients with chronic airway diseases (2022 edition). Zhonghua Kou Qiang Yi Xue Za Zhi 57, 455–461 (2022).
Wang, Z. M. et al. Consensus of experts on the oral health management and medical risk prevention for the patients with chronic airway diseases (2022 edition). Chin. J. Stomatol 57, 455–461 (2022).
Kim, S. J. et al. Chronic periodontitis and community-acquired pneumonia: a population-based cohort study. BMC Pulm. Med. 19, 268 (2019).
Klompas, M., Speck, K., Howell, M. D., Greene, L. R. & Berenholtz, S. M. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-analysis. JAMA Intern Med. 174, 751–761 (2014).
Fischer, R. G. et al. What is the future of periodontal medicine? Braz. Oral. Res. 35, e102 (2021).
Baker, D. et al. The association between accessing dental services and nonventilator hospital-acquired pneumonia among 2019 Medicaid beneficiaries. Infect. Control Hosp. Epidemiol. 44, 959–961 (2023).
Apessos, I., Voulgaris, A., Agrafiotis, M., Andreadis, D. & Steiropoulos, P. Effect of periodontal therapy on COPD outcomes: a systematic review. BMC Pulm. Med. 21, 92 (2021).
Rosland, A. et al. Effect of periodontal therapy on lung function: a twelve-month follow-up intervention study. Respir. Res. 26, 172 (2025).
Ramar, K. et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. J. Clin. Sleep. Med. 11, 773–827 (2015).
Zhang, Y., Luo, M. & Ming, Y. Global burden of cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2021. BMC Gastroenterol. 25, 641 (2025).
Collaborators, G. M. Global burden of metabolic dysfunction-associated steatotic liver disease, 1990-2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Gastroenterol. Hepatol. 11, 463–494 (2026).
Li, H., Shi, M., Yuan, R., Wang, H. & Li, Y. Association between periodontitis and non-alcoholic fatty liver disease in community-dwelling adults: a systematic review and meta-analysis. Sci. Rep. 16, 16217 (2026).
Kuraji, R., Sekino, S., Kapila, Y. & Numabe, Y. Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an emerging concept of oral-liver axis. Periodontol 2000 87, 204–240 (2021).
Vegda, H. S. et al. Role of nonalcoholic fatty liver disease in periodontitis: a bidirectional relationship. Cureus 16, e63775 (2024).
Juzbasic, M. et al. Interaction between periodontitis and MASLD: pathophysiological associations and possibilities of prevention and therapy. Biomedicines 13, 1346 (2025).
Wang, M. et al. Periodontitis salivary microbiota exacerbates nonalcoholic fatty liver disease in high-fat diet-induced obese mice. iScience 26, 106346 (2023).
Jin, Y. et al. The triadic relationship between nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease: From molecular mechanisms to clinical management. Curr. Probl. Cardiol. 50, 103170 (2025).
Management, Clinical Studies on Hepatitis (CSH), and Hepatology within the context of a Contract Research Organization (CRO) or Chief Scientific Officer (CSO). Expert consensus on viral hepatitis health management (2021). Chin. J. Health Manag. 15, 323–331 (2021).
Krishnamurthy Bonanthaya, E. P., Suvy Manuel, Vinay V. Kumar, Anshul Rai (eds). in Oral and Maxillofacial Surgery for the Clinician, 1st edn, (Springer Singapore, 2021).
Bakhsh, A. A., Shabeeh, H., Mannocci, F. & Niazi, S. A. A review of guidelines for antibiotic prophylaxis before invasive dental treatments. Appl. Sci. 11, 311 (2021).
Yiman, T. & Lixin, Q. Clinical considerations of organ transplant patients receiving implant therapy. Chin. J. Oral. Implantol. 29, 297–302 (2024).
Brandenburg, V. M. et al. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 77, 1566–1571 (2004).
Hudson, D. et al. Periodontal disease and cirrhosis: current concepts and future prospects. eGastroenterology 3, e100140 (2025).
Xu, X. et al. Expert consensus on endodontic therapy for patients with systemic conditions. Int. J. Oral. Sci. 16, 45 (2024).
Kuraji, R., Shiba, T., Dong, T. S., Numabe, Y. & Kapila, Y. L. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. World J. Gastroenterol. 29, 967–996 (2023).
Somacarrera, M. L., Lucas, M., Cuervas-Mons, V. & Hernandez, G. Oral care planning and handling of immunosuppressed heart, liver, and kidney transplant patients. Spec. Care Dent. 16, 242–246 (1996).
Kamata, Y. et al. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial. Trials 21, 291 (2020).
Kamata, Y. et al. Periodontal treatment and usual care for nonalcoholic fatty liver disease: a multicenter, randomized controlled trial. Clin. Transl. Gastroenterol. 13, e00520 (2022).
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L. & Perkovic, V. Chronic kidney disease. Lancet 398, 786–802 (2021).
Collaborators, G. B. D. C. K. D. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 2461–2482 (2025).
He, G. et al. Chronic kidney disease burden from 1990 to 2023 in China: national and provincial insights from the Global Burden of Diseases study 2023. Lancet Reg. Health West Pac. 68, 101776 (2026).
Shimizu, Y. et al. Association between periodontitis and chronic kidney disease by functional atherosclerosis status among older Japanese individuals: a cross-sectional study. J. Clin. Periodontol. 50, 430–439 (2023).
Lopez-Sanz, L. et al. Chronic kidney disease and chronic oral inflammatory diseases: a systematic review and meta-analysis of periodontitis and apical periodontitis. J. Clin. Med. 14, 7947 (2025).
Schmidt-Lauber, C. et al. Association of periodontitis with reduced kidney function and albuminuria in early chronic kidney disease: a population-based study. Int. J. Oral Sci. 18, 33 (2026).
He, T., Li, X., Liao, C. J., Feng, X. Y. & Guo, X. Y. Association of periodontal disease with the prognosis of chronic kidney disease: a meta-analysis. J. Chin. Med. Assoc. 88, 170–177 (2025).
Sharma, P. et al. Oxidative stress links periodontal inflammation and renal function. J. Clin. Periodontol. 48, 357–367 (2021).
Ganimusa, I., Chew, E. & Lu, E. M. Vitamin D deficiency, chronic kidney disease and periodontitis. Medicina 60, 420 (2024).
Santos-Paul, M. A. et al. Cardiovascular risk reduction with periodontal treatment in patients on the waiting list for renal transplantation. Clin. Transpl. 33, e13658 (2019).
Nylund, K. M. et al. Oral health in patients with renal disease: a longitudinal study from predialysis to kidney transplantation. Clin. Oral. Investig. 22, 339–347 (2018).
Ishimaru, M. et al. Risk of surgical site infections after tooth extraction in CKD: a retrospective real-world study in Japan. Clin. J. Am. Soc. Nephrol. 20, 582–584 (2025).
Li, S. et al. Periodontal disease and chronic kidney disease: mechanistic insights and novel therapeutic perspectives. Front. Cell Infect. Microbiol. 15, 1611097 (2025).
da Silva, T. A., Abreu, L. G. & Esteves Lima, R. P. A meta-analysis on the effect of periodontal treatment on the glomerular filtration rate of chronic kidney disease individuals: a systematic review and meta-analysis was conducted to assess the impact of the periodontal treatment on the glomerular filtration rate of individuals with chronic kidney disease. Spec. Care Dent. 41, 670–678 (2021).
Almeida, S., Figueredo, C. M., Lemos, C., Bregman, R. & Fischer, R. G. Periodontal treatment in patients with chronic kidney disease: a pilot study. J. Periodontal Res. 52, 262–267 (2017).
Wongsuwanlert, M. et al. Short-term assessment of non-surgical periodontal therapy reduces oral pathogens and pro-inflammatory cytokines, enhancing clinical outcomes in patients with chronic kidney disease. BMC Oral Health 26, 1604 (2026).
Collaborators, G. B. D. C. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1565–1586 (2025).
Xia, C., Li, H., Wu, C. & Chen, W. Cancer burden and control in China: landscape, trends and challenges. Nat. Rev. Clin. Oncol. 23, 694–711 (2026).
Yuan J, W. S. et al. Risk of cancer in periodontal disease: an umbrella review of meta-analyses. Front. Immunol. 17, 1–13 (2026).
Nwizu, N., Wactawski-Wende, J. & Genco, R. J. Periodontal disease and cancer: epidemiologic studies and possible mechanisms. Periodontology 83, 213–233 (2020).
Higham, J. & Scannapieco, F. A. Epidemiological associations between periodontitis and cancer. Periodontology 96, 74–82 (2024).
Sasaki, M. et al. Periodontitis and postoperative inflammation in gastric cancer patients: propensity score analysis. Oral Dis. 30, 4691–4704 (2024).
Davis, D. D., Hanley, M. E. & Cooper, J. S. Osteoradionecrosis (Archived). StatPearls Publishing (2023).
Iqbal, Z. & Kyzas, P. Analysis of the critical dose of radiation therapy in the incidence of osteoradionecrosis in head and neck cancer patients: a case series. BDJ Open 6, 18 (2020).
Moharrami, M. et al. Defining the optimal radiation thresholds for stratifying jaw osteoradionecrosis risk in head and neck cancer. Radiother. Oncol. 209, 110996 (2025).
Mazzetti, T. et al. Required time for pre-oncological dental management - a rapid review of the literature. Oral. Oncol. 134, 106116 (2022).
Watson, E. E. et al. Development and standardization of an osteoradionecrosis classification system in head and neck cancer: implementation of a risk-based model. J. Clin. Oncol. 42, 1922–1933 (2024).
Mealey, B. L., Semba, S. E. & Hallmon, W. W. The head and neck radiotherapy patient: part 2-management of oral complications. Compendium 15, 442–444 (1994).
Xia, J. et al. Expert consensus on the prevention and treatment of radiochemotherapy-induced oral mucositis. Int J. Oral. Sci. 17, 54 (2025).
Jané-Salas E, E.-Á. Y., Álvarez-García R, García Miragall E, Clemente-Tejada L, Beorlegui-Murillo P. Multidisciplinary Consensus on Oral Care in Cancer Patients https://semo.es/wp-content/uploads/2022/10/MULTIDISCIPLINARI-CONSENSUS_2.pdf (2022).
Hong, C. H. et al. A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 18, 1007–1021 (2010).
Pfister, D. G. et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 18, 873–898 (2020).
Han, Y. et al. The tendency of anemia of inflammation in periodontal diseases. Clin. Sci. 137, 251–264 (2023).
Huang, L. G., Yu, C. C., Lin, M. C., Wang, Y. H. & Chang, Y. C. Association between periodontitis and hematologic cancer: an NHIRD cohort study in Taiwan. Cancers 16, 1671 (2024).
Gokhale, S. R., Sumanth, S. & Padhye, A. M. Evaluation of blood parameters in patients with chronic periodontitis for signs of anemia. J. Periodontol. 81, 1202–1206 (2010).
Khan, M. A., Lal, N., Chandra, T., Ali, W. & Ismail, H. Association of ABO phenotype, rhesus factor, platelet count and hemoglobin level with oral hygiene status and severity of chronic periodontitis. J. Oral. Biol. Craniofacial Res. 14, 730–734 (2024).
Yuan, Q. et al. Ligature-induced periodontitis promotes Dnmt3a(R878H)-driven clonal hematopoiesis. Haematologica 111, 2047–2060 (2026).
Sharan, J. et al. Gingival hyperplasia: an initial oral manifestation of acute myeloid leukemia. J. Indian Soc. Periodontol. 27, 201–206 (2023).
Zadik, Y. et al. MASCC/ISOO clinical practice statement: dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy. Support Care Cancer 33, 853 (2025).
Miller, C., Rhodus, N. L., Treister, N. S., Stoopler, E. T. & Kerr, A. R. Little and Falace’s Dental Management of the Medically Compromised Patient 10th edn (Elsevier Health Sciences, 2023).
Oyaizu, K. et al. Periodontal treatment in severe aplastic anemia. J. Periodontol. 76, 1211–1216 (2005).
Nickles, K., Wohlfeil, M., Alesci, S., Miesbach, W. & Eickholz, P. Comprehensive treatment of periodontitis in patients with von Willebrand disease. J. Periodontol. 81, 1432–1440 (2010).
Lv, X. et al. Initial periodontal therapy for seven patients with aplastic anemia and drug-induced gingival overgrowth: a case series report. BMC Oral. Health 25, 847 (2025).
Herrera, D. et al. Treatment of stage IV periodontitis: the EFP S3 level clinical practice guideline. J. Clin. Periodontol. 49, 4–71 (2022).
Society of Periodontology, C. S. A. [Consensus of Chinese experts on diagnosis of severe periodontitis and treatment principles of periodontitis in special population]. Zhonghua Kou Qiang Yi Xue Za Zhi 52, 67–71 (2017).
Bertolani, Y., Garcia-Arumi, C., Goncharova, T., Arnaiz-Camacho, A. & Garcia-Arumi, J. Choroidal metastasis secondary to follicular thyroid carcinoma successfully managed with larotrectinib: a case report and review of the literature. Ann. Endocrinol. 86, 101675 (2025).
Yang, L., Zhang, S., Wang, X., Yang, J. & Chen, M. Intelligent prediction of thyroid cancer in China based on GBD data and hospital electronic medical records: disease burden analysis combined with multiple machine learning models. Front. Endocrinol. 16, 1644396 (2025).
Inchingolo, F. et al. Bidirectional association between periodontitis and thyroid disease: a scoping review. Int. J. Environ. Res. Public Health 21, 860 (2024).
Puthiyapurayil, S., Vadakkekuttical, R. J., Kesavan, T. N. & Kanakkath, H. Association between periodontal parameters and thyroid markers in autoimmune hypothyroidism: a cross-sectional study. J. Periodontol. 97, 569–579 (2025).
Wang, H. et al. Associations between thyroid function and periodontitis: a machine learning approach using NHANES. Int. Dent. J. 75, 100921 (2025).
Mancini, A. et al. Thyroid hormones, oxidative stress, and inflammation. Mediat. Inflamm. 2016, 6757154 (2016).
Dhanwal, D. K. Thyroid disorders and bone mineral metabolism. Indian J. Endocrinol. Metab. 15, S107–112 (2011).
Bhankhar, R. R., Hungund, S., Kambalyal, P., Singh, V. & Jain, K. Effect of nonsurgical periodontal therapy on thyroid stimulating hormone in hypothyroid patients with periodontal diseases. Indian J. Dent. Res. 28, 16–21 (2017).
Hong, C. H., Scobey, M. W., Napenas, J. J., Brennan, M. T. & Lockhart, P. B. Dental postoperative bleeding complications in patients with suspected and documented liver disease. Oral. Dis. 18, 661–666 (2012).
Acknowledgements
This work was supported by the National Key Research and Development Program of China (No. 2023YFC2506300), National Natural Science Foundation of China (No. 82370975), National Natural Science Foundation of China (No. 82571104), Natural Science Foundation of Liaoning Province (No. 2025-MSLH-745).
Author information
Author notes
These authors contributed equally: Fengxue Geng, Li Lin
Authors and Affiliations
Department of Periodontics, School and Hospital of Stomatology, China Medical University, Shenyang, China
Fengxue Geng, Li Lin, Dongmei Zhang, Chen Li & Xida Zhao
Department of Periodontology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China
Zhongchen Song
Department of Periodontology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China
Fuhua Yan
Department of Periodontics, Affiliated Hospital of Stomatology, Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, China
Yan Xu
Laboratory of Tissue Regeneration and Immunology and Department of Periodontics, Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, School of Stomatology, Capital Medical University, Beijing, China
Yi Liu
Department of Periodontics and Oral Mucosa Diseases, Dalian Stomatological Hospital, Dalian, China
Jiang Sun
Department of Periodontology, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology & Research Center of Engineering, Beijing, China
Qingxian Luan
Department of Periodontology, National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology & Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health, Peking University School and Hospital of Stomatology, Beijing, China
Wenjie Hu
Department of Periodontology, School and Hospital of Stomatology, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, China
Shaohua Ge
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi International Joint Research Center for Oral Diseases, Department of Periodontology, School of Stomatology, The Fourth Military Medical University, Xi’an, China
Faming Chen
Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, China
Chuanjiang Zhao
Department of Endocrinology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Jie Qiao
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China
Xiaoping Chen
West China Hospital, Sichuan University, Chengdu, China
Xianghao Zuo
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China
Xinghui Liu
Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University; Beijing Institute of Respiratory Medicine, Beijing Key Laboratory of Multimodal Intelligent Diagnosis and Treatment System for Respiratory Diseases, Beijing, China
Li An
Department of Stomatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
Zuomin Wang
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Periodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
Yi Ding
Department of Periodontics and Oral Biology, Liaoning Provincial Key Laboratory of Oral Diseases, School and Hospital of Stomatology, China Medical University, Shenyang, China
Yaping Pan
Authors
- Fengxue Geng
- Li Lin
- Zhongchen Song
- Fuhua Yan
- Yan Xu
- Yi Liu
- Jiang Sun
- Qingxian Luan
- Wenjie Hu
- Shaohua Ge
- Faming Chen
- Chuanjiang Zhao
- Jie Qiao
- Xiaoping Chen
- Xianghao Zuo
- Xinghui Liu
- Li An
- Zuomin Wang
- Dongmei Zhang
- Chen Li
- Xida Zhao
- Yi Ding
- Yaping Pan
Contributions
Conceptualization and Investigation, Y.P. Pan and Y. Ding; Supervision, Y.P. Pan and Y. Ding; Original draft, F.X. Geng and L. Lin; Review and editing, F.X. Geng, L. Lin, Z.C. Song, F.H. Yan, Y. Xu, Y. Liu, J. Sun, Q.X. Luan, W.J. Hu, S.H. Ge, F.M. Chen, C.J. Zhao, J. Qiao, X.P. Chen, X.H. Zuo, X.H. Liu, L. An, Z.M. Wang, D.M. Zhang, C. Li, X.D. Zhao, Y. Ding, and Y.P. Pan.
Corresponding authors
Correspondence to Yi Ding or Yaping Pan.
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Geng, F., Lin, L., Song, Z. et al. Expert consensus on periodontal management for medically compromised patients. Int J Oral Sci 18, 74 (2026). https://doi.org/10.1038/s41368-026-00471-2
Received: 31 March 2026
Accepted: 21 September 2026
Published: 20 November 2026
Version of record: 20 November 2026
DOI: https://doi.org/10.1038/s41368-026-00471-2
来源:Nature 健康护理主题 · nature.com